MGTX
MeiraGTx Holdings plc
There isn't enough reported data to score MGTX yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
MGTX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Under pressure | |
| Strong |
MGTX's profitability and balance sheet are currently strong, but its cash flow is under pressure. There isn't enough data to rate its revenue.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
MGTX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 11x | $8.79 | — |
| Cheap | 13x | $10.39 | +18% |
| Fair | 15x | $12.22 | +39% |
| Expensive | 19x | $15.50 | +76% |
Historical ranges are pointers, not guarantees.
MGTX has the edge over NVO in the historical PE scenario, which offers more potential upside but is not a forecast.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
MGTX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect MGTX's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
MGTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.80 | +$2.90 |
| Q2 2026 | $0.71 | +$2.74 |
| Q1 2026 | -$1.48 | +$0.83 |
| Q4 2025 | -$1.42 | +$0.70 |
| Q3 2025 | -$2.10 | -$0.87 |
| Q2 2025 | -$2.03 | -$0.61 |
| Q1 2025 | -$2.31 | -$1.12 |
| Q4 2024 | -$2.12 | -$0.63 |
MGTX has returned to profit: it earned $0.80 per share over the past year, after losing money the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over MGTX on earnings, with more consistent year-over-year improvement.
MGTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.8M | +1074% |
| Q2 2026 | $321.4M | +8609% |
| Q4 2025 | $75.4M | +252% |
| Q3 2025 | $410K | -96% |
| Q2 2025 | $3.7M | +1209% |
| Q3 2024 | $10.9M | +114% |
| Q2 2024 | $282K | -92% |
| Q1 2024 | $697K | -79% |
MGTX's revenue is growing: $5M last quarter, up 1074% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1036% | +10196 points |
| Q2 2026 | 76% | +1290 points |
| Q1 2026 | -13931% | N/A |
| Q4 2025 | 35% | +182 points |
| Q3 2025 | -11232% | -10865 points |
| Q2 2025 | -1214% | +15066 points |
| Q4 2024 | -147% | N/A |
| Q3 2024 | -367% | +275 points |
MGTX's operating margin was −1036% last quarter, up 10196 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over MGTX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over MGTX on profitability, with a higher operating margin.
MGTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$26.3M | -$13.5M |
| Q2 2026 | -$38.9M | +$6.3M |
| Q1 2026 | $15.8M | +$54.3M |
| Q4 2025 | $46.4M | +$70.9M |
| Q3 2025 | -$12.8M | +$12.9M |
| Q2 2025 | -$45.2M | -$24.4M |
| Q1 2025 | -$38.5M | -$119K |
| Q4 2024 | -$24.5M | -$6.9M |
MGTX has burned cash in almost every quarter: −$3M over the past year, against −$121M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over MGTX on cash generation, producing positive trailing cash flow while its opponent burns cash.
MGTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +3.1M shares |
| 1 year | +20% | +15.9M shares |
| 3 years | +63% | +37.4M shares |
| 5 years | +119% | +52.7M shares |
| Available history | +192% | +63.7M shares |
MGTX has 97M diluted shares, up 20% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $18.2M |
| Q4 2022 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over MGTX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
MGTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -0.2x | Net Cash |
MGTX has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
MGTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.5 | Neutral |
| Stochastic | 6.8 | Oversold |
MGTX's weekly RSI is 38 (neutral) and its Stochastic is 7 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
MGTX PE vs Healthcare Sector
| Metric | MGTX | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 26x | 57% below |
MGTX is trading at 11x earnings, a 57% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over MGTX on valuation relative to its sector.
MGTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.77 | 10% below |
| 20 week MA | $11.8 | 26% below |
| 50 week MA | $9.90 | 11% below |
| 100 week MA | $8.49 | 3.5% above |
| 200 week MA | $7.11 | 24% above |
MGTX has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
MGTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $20.1 | $16.4 | -18% |
| 2021 | $16.4 | $22.4 | +36% |
| 2022 | $22.4 | $6.01 | -73% |
| 2023 | $6.01 | $7.02 | +17% |
| 2024 | $7.02 | $6.21 | -12% |
| 2025 | $6.21 | $7.97 | +28% |
| 2026 YTD | $7.97 | $8.79 | +10% |
MGTX has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.